Biology subjects

Alderwick, L. J.

Publications and source records attributed to Alderwick, L. J..

4 recordsLinked to original sources

bioRxiv2021

Mycobacterium tuberculosis modifies cell wall carbohydrates during biofilm growth with a concomitant reduction in complement activation

There is an urgent need for drugs, new vaccines, and diagnostics for TB. It is recognised that research needed for the development of new vaccines for TB needs to be underpinned by understanding both the molecular and cellular mechanisms of host-pathogen interactions and how the immune response can be modulated to achieve protection with the use of a new vaccine for TB. Complement interacts with and orchestrates many aspects of the innate and adaptive immune responses and activation by Mycobacterium tuberculosis can be triggered by all three pathways. However, little is known about the contribution of each of these pathways during TB disease, particularly with respect to mycobacterial phenotype. There is strong evidence for extracellular communities of M. tuberculosis during TB disease (biofilms) that are found in the acellular rim of granulomas. These biofilms have been observed in cavities in lung resections from TB patients and are likely to be present in post-primary TB episodes in necrotic lesions. Our study aimed to understand more about the interactions between M. tuberculosis biofilms and complement activation, to determine which mycobacterial cell wall components are altered during biofilm growth, and how their alteration contributes to modulation of the complement response. We show that the lectin pathway has a reduced role compared to the classical pathway in initiating complement activation in biofilm bacteria. Analyses of the M. tuberculosis biofilm cell wall carbohydrate fractions revealed that there was reduced -glucan compared to planktonically-grown bacteria. Reduced C3b/iC3b deposition directly onto biofilm carbohydrates was observed which was consistent with both the observed reduction of C3b/iC3b deposition on biofilm bacilli and a reduction in the contribution of the lectin pathway in initiating complement activation on whole bacteria from biofilms, compared to planktonically-grown bacteria.

immunology↗

bioRxiv2020

Azetidines kill Mycobacterium tuberculosis without detectable resistance by blocking mycolate assembly.

Tuberculosis (TB) is the leading cause of global morbidity and mortality resulting from infectious disease, with over 10 million new cases and 1.5 million deaths in 2019. This global emergency is exacerbated by the emergence of multi-drug-resistant MDR-TB and extensively-drug-resistant XDR-TB, therefore new drugs and new drug targets are urgently required. From a whole-cell phenotypic screen a series of azetidines derivatives termed BGAz, that elicit potent bactericidal activity with MIC99 values <10 M against drug-sensitive Mycobacterium tuberculosis and MDR-TB were identified. These compounds demonstrate no detectable drug resistance. Mode of action and target deconvolution studies suggest that these compounds inhibit mycobacterial growth by interfering with cell envelope biogenesis, specifically late-stage mycolic acid biosynthesis. Transcriptomic analysis demonstrates that the BGAz compounds tested display a mode of action distinct from existing mycobacterial cell-wall inhibitors. In addition, the compounds tested exhibit toxicological and PK/PD profiles that pave the way for their development as anti-tubercular chemotherapies.

microbiology↗

bioRxiv2020

New mechanisms of radioiodide uptake revealed via a novel high throughput drug screening approach in thyroid cancer

New combinatorial drug strategies are urgently needed to improve radioiodide (RAI) uptake and efficiently ablate thyroid cancer cells, thereby addressing recurrent and metastatic disease. Cellular iodide uptake is accomplished solely by the sodium iodide symporter (NIS), but the complexity of NIS functional regulation and a lack of amenable high-throughput screening assays has impeded progress. We utilised mutated yellow fluorescent protein (YFP) as a surrogate biosensor of intracellular iodide for [~]1200 FDA-approved drugs, allowing us to appraise the impact of 73 leading compounds at 10 doses on 125I uptake in thyroid cancer cell lines. Subsequent mechanistic analysis suggests three predominant modes of drug action: Firstly, a number of drugs inhibited specific regulation of NIS function by the protein VCP. Secondly, some drugs enhanced transcriptional or post-transcriptional regulation of NIS expression. Thirdly, several drugs strongly implicated proteasomal degradation and the unfolded protein response in the cellular processing of NIS. Exploiting these mechanistic insights, multiple compounds gave striking increases in radioiodide uptake when combined with the drug SAHA. Importantly, our new drug combination strategies were also effective in human primary thyrocytes, suggesting they target endogenous NIS physiology. In patients with papillary thyroid cancer, genes involved in proteostasis were remarkably altered and predicted significantly worse outcome, but only in those patients who received RAI therapy. Collectively, we therefore propose a new model of intracellular NIS processing, and identify key nodes which may now be druggable in patients with aggressive thyroid cancer. SUMMARYOur data identify FDA-approved drugs that enhance radioiodide uptake outside of the canonical pathways of NIS processing, leading to a new mechanistic understanding of endogenous NIS function which is subverted in cancer.

cancer biology↗

bioRxiv2018

Utilisation of the Prestwick Chemical Library (R) to identify drugs that inhibit the growth of Mycobacteria

Tuberculosis (TB) is an infectious bacterial disease that kills approximately 1.3 million people every year. Despite global efforts to reduce both the incidence and mortality associated with TB, the emergence of drug resistant strains has slowed any progress made towards combating the spread of this deadly disease. The current TB drug regimen is inadequate, takes months to complete and poses significant challenges when administering to patients suffering from drug resistant TB. New treatments that are faster, simpler and more affordable are urgently required. Arguably, a good strategy to discover new drugs is to start with an old drug. Here, we have screened a library of 1200 FDA approved drugs from the Prestwick Chemical library (R) using a GFP microplate assay. Drugs were screened against GFP expressing strains of Mycobacterium smegmatis and Mycobacterium bovis BCG as surrogates for Mycobacterium tuberculosis, the causative agent of TB in humans. We identified several classes of drugs that displayed antimycobacterial activity against both M. smegmatis and M. bovis BCG, however each organism also displayed some selectivity towards certain drug classes. Variant analysis of whole genomes sequenced for resistant mutants raised to florfenicol, vanoxerine and pentamidine highlight new pathways that could be exploited in drug repurposing programmes.

microbiology↗